349 related articles for article (PubMed ID: 33954821)
1. Effect of cytotoxic chemotherapy on bone health among breast cancer patients. Does it require intervention?
Nisha Y; Dubashi B; Bobby Z; Sahoo JP; Kayal S
Support Care Cancer; 2021 Nov; 29(11):6957-6972. PubMed ID: 33954821
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
4. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.
Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede HJ
Med J Aust; 2019 Sep; 211(5):224-229. PubMed ID: 31318068
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
6. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
7. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
8. Denosumab and the current status of bone-modifying drugs in breast cancer.
Lee BL; Higgins MJ; Goss PE
Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
[TBL] [Abstract][Full Text] [Related]
9. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
11. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
13. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
15. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
16. Bone targeted therapies in advanced breast cancer.
Biskup E; Cai F; Vetter M
Swiss Med Wkly; 2017 Jul; 147():w14440. PubMed ID: 28695563
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials.
Mei M; Xiang Z; Yang J; Xiang R
Curr Probl Cancer; 2020 Apr; 44(2):100507. PubMed ID: 31732237
[TBL] [Abstract][Full Text] [Related]
18. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
[TBL] [Abstract][Full Text] [Related]
19. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
20. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
